Table 1 Clinical characteristics of the 6 CRPC patients.
From: Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
Patient ID | Age | PSA level at diagnosis of Pca (ng/ml) | The Gleason score at diagnosis of Pca | The TNM stage at diagnosis of Pca | First-line therapy | Second-line therapy | Time from treatment start to CRPC (mo) | Time from CRPC to now (mo) | PSA level at present (ng/ml) | The TNM stage at present |
|---|---|---|---|---|---|---|---|---|---|---|
Patient #1 | 82 | 8.88 | 4 + 5 = 9 | cT2cN0M0 | Goserelin, bicalutamide | None | 9 | 0.5 | 5.85 | cT4N0M0 |
Patient #2 | 82 | 56.53 | 4 + 3 = 7 | cT3bN1M0 | Goserelin, bicalutamide | None | 15.9 | 3.2 | 18.57 | cT3bN0M0 |
Patient #3 | 86 | 55.16 | 4 + 4 = 8 | cT2cN0M0 | Goserelin, bicalutamide | None | 15.9 | 3.7 | 11.76 | cT2cN0M0 |
Patient #4 | 78 | >149 | 4 + 3 = 7 | cT4N0M0 | Bilateral orchidectomy, bicalutamide | Docetaxel, Abiraterone | 12.5 | 18.6 | 117.95 | cT4N0M1 |
Patient #5 | 65 | 15.6 | 4 + 4 = 8 | cT3bN1M1a | Bilateral orchidectomy, bicalutamide | None | 27.8 | 2.6 | 0.9 | cT4N1M1 |
Patient #6 | 70 | 72.72 | Small-cell NEPC | cT4N1M1 | Docetaxel | None | 14.8 | 3.7 | 7.18 | cT3bN0M1 |
